气管套管上发声的早期决策分析卫生经济学模型:已知什么与需解决什么
该研究构建了一个早期决策分析卫生经济学模型,从英国国家医疗服务体系视角,比较气管套管上发声(ACV)与常规护理(UC)在假设的ICU气管切开患者队列(63岁,64%男性)中的成本效果。模型参数来自文献回顾和专家意见。基础案例分析显示ACV可能具有成本效益,优于UC,节省费用9,488英镑(12,808美元)并获得0.395个质量调整生命年。大多数敏感性分析显示ACV优于UC,但当ACV对ICU和病房住院时间有负面影响或对脱机速度无影响时,ACV不具有成本效益。
要点
- 在基础案例分析中,ACV与UC相比,节省费用9,488英镑(12,808美元)并获得0.395个质量调整生命年,ACV优于UC。
- ACV在ICU的每日成本为75至89英镑(101至120美元),大部分成本归因于实施所需的人力资源。
- 大多数敏感性分析显示ACV优于UC(成本更低且更有效),但当ACV对ICU和病房住院时间有负面影响或对脱机速度无影响时,ACV不具有成本效益。
- 成本的主要驱动因素是ACV是否影响脱机速度和ICU住院时间;效果的两个主要驱动因素是ACV是否影响患者转入的终末状态以及ACV是否对生活质量有持续积极影响。
- 作者认为,尽管ACV需要言语语言病理学家的大量投入,但显示出很强的成本效益潜力,决策者没有理由不采用ACV,延迟采用可能导致机会成本损失。
适用人群与场景
- 假设的普通ICU气管切开患者队列,年龄63岁,64%为男性。
- 视角为英国国家医疗服务体系。
研究设计与关键结果
- 研究类型为早期决策分析卫生经济学模型,比较ACV与常规护理(UC)。
- 模型参数来自文献回顾和专家意见。
- 基础案例分析:ACV优于UC,节省费用9,488英镑(12,808美元)并获得0.395个质量调整生命年。
- ACV在ICU的每日成本为75至89英镑(101至120美元),大部分成本归因于实施所需的人力资源。
- 大多数敏感性分析显示ACV优于UC(成本更低且更有效);当ACV对ICU和病房住院时间有负面影响或对脱机速度无影响时,ACV不具有成本效益。
- 成本的主要驱动因素是ACV是否影响脱机速度和ICU住院时间;效果的两个主要驱动因素是ACV是否影响患者转入的终末状态以及ACV是否对生活质量有持续积极影响。
证据类型、等级与局限
- 证据类型:早期决策分析卫生经济学模型。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,尽管ACV需要言语语言病理学家的大量投入,但显示出很强的成本效益潜力。
- 作者认为,决策者没有理由不采用ACV,延迟采用可能导致机会成本损失。
- 作者认为,改善重症监护研究中死亡率和效用数据的报告将提高早期决策分析模型的可靠性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Above cuff vocalization (ACV) is used in patients with a tracheostomy in the ICU despite limited evidence. This early-stage decision-analytic model (DAM) for ACV evaluates the expected cost-effectiveness exploring the impact of uncertainty to identify key drivers of cost and effect and critical further research priorities.
PERSPECTIVE: U.K. National Health Service.
SETTING: Hypothetical cohort of general ICU patients with a tracheostomy, 63 years old, 64% male.
METHODS: A de novo decision-analytic health economic model comparing ACV to usual care (UC). Model parameters were acquired from the literature review and expert opinion. One-way sensitivity analyses were conducted to identify key drivers of cost-effectiveness.
RESULTS: The daily cost of ACV in the ICU ranged from £75 to 89 (USD 101-120), with most of this cost attributable to staff resources for delivery. The base-case scenario revealed ACV is potentially cost-effective, dominating UC with cost savings of £9,488 (USD 12,808) and 0.395 Quality-Adjusted Life Years gained. Most sensitivity analyses revealed that ACV dominated UC, costing less and being more effective. When ACV had a negative impact on ICU and ward length of stay (LoS), or had no effect on the speed of weaning, it was not cost-effective. The primary driver of cost was whether ACV affected the speed of weaning and ICU LoS. The two primary drivers of effect were: i) whether ACV impacted which end state a patient transitioned to and ii) whether ACV had a sustained positive impact on quality of life.
CONCLUSIONS: Despite the substantial input required from speech-language pathologists-a typically scarce resource in ICU settings-ACV demonstrates strong potential for cost-effectiveness. There is no reason for decision-makers to de-adopt ACV, and delaying adoption may result in loss of opportunity costs. Improved reporting of mortality and utility data in critical care research would increase the reliability of early-stage DAMs.
参考来源
- Mills CS, Michou E, Bellamy MC, et al. An Early-Stage Decision-Analytic Health Economic Model of Above Cuff Vocalization: What Do We Know and What Do We Need to Resolve? Crit Care Explor. 2025. PMID: 41359307. doi:10.1097/CCE.0000000000001353
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。